Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin. 2014;64(1):9–29. Erratum in: CA Cancer J Clin. 2014;64:364.
   PubMed Web of Science ®Google Scholar
• NationalCancerInstitute.[ Internet]. [cited 2021 Aug 5]. Available from: https://seer.cancer.gov/statfacts/html/thyro.html.
   Google Scholar
• Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614–617.
   PubMed Web of Science ®Google Scholar
• Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48:23–35.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Sm F, Mr G, et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 2020;S1044–579X:30249–30252.
   Google Scholar
• Antonelli A. Thyroid cancer in patients with hepatitis C infection. JAMA. 1999;281(17):1588.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Baldini E, et al. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert Rev Anticancer Ther. 2016;16:1109–1118.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Bocci G, Di Desidero T, et al. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncol Rep. 2018;39:2306–2314.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Bocci G, Di Desidero T, et al. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018;39:2225–2234.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Elia G, Ragusa F, et al. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 2020;9(S1):S28–S42.
   PubMedGoogle Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer. Curr Genomics. 2011;12(8):626–631.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, Fallahi P, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014;99(4):E572–E581.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine. 2012;59(2):218–222.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2012;97(4):E528–E536.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, La Motta C, Elia G, et al. Antineoplastic effect of lenvatinib and vandetanib in primary anaplastic thyroid cancer cells obtained from biopsy or fine needle aspiration. Front Endocrinol (Lausanne). 2018;9:764.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Osamura RY, Klöppel G, et al., editors. WHO classification of tumours of endocrine organs. 4th. IARC WHO Classification of Tumours. Lyon: IARC; 2017.
   Google Scholar
• Volante M, Bussolati G, Papotti M. The story of poorly differentiated thyroid carcinoma: from Langhans’ description to the Turin proposal via Juan Rosai. Semin Diagn Pathol. 2016;33(5):277–283.
   PubMed Web of Science ®Google Scholar
• Fugazzola L, Elisei R, Fuhrer D, et al. european thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019;8:227–245.
   PubMed Web of Science ®Google Scholar
• Durante C, Montesano T, Torlontano M, et al. PTC Study Group. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98(2):636–642.
   PubMed Web of Science ®Google Scholar
• Gruber JJ, Colevas AD. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist. 2015;20:113–126.
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th. Chicago: Springer; 2002.
   Google Scholar
• Lamartina L, Cooper DS. Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view. Endocrine. 2015;50(1):67–71.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR. American Thyroid Association (ATA). Guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
   PubMed Web of Science ®Google Scholar
• Miccoli P, Antonelli A, Iacconi P, et al. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow-up. Surgery. 1993;114:1097–1101.
   PubMed Web of Science ®Google Scholar
• Valerio L, Pieruzzi L, Giani C, et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol). 2017;29(5):316–324.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Ain KB, Asa SL, et al., American Thyroid Association anaplastic thyroid cancer guidelines taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 22(11): 1104–1139. 2012.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Ruffilli I, Centanni M, et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–208.
   PubMed Web of Science ®Google Scholar
• Nair A, Lemery SJ, Yang J, et al. FDA approval summary: lenvatinib for progressive, radio-iodine–refractory differentiated thyroid cancer. Clin Cancer Res. 2015;21(23):5205–5208.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Centanni M, Virili C, et al. Sunitinib in the treatment of thyroid cancer. Curr Med Chem. 2019;26(6):963–972.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569–580.
   PubMed Web of Science ®Google Scholar
• Khatami F, Tavangar SM. A review of driver genetic alterations in thyroid cancers. Iran J Pathol. 2018;13:125–135. Spring.
   PubMedGoogle Scholar
• Al-Jundi M, Thakur S, Gubbi S, et al. Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers (Basel). 2020;12:2104.
   PubMed Web of Science ®Google Scholar
• Tirrò E, Martorana F, Romano C, et al. Molecular alterations in thyroid cancer: from bench to clinical practice. Genes (Basel). 2019;10(9):709.
   Web of Science ®Google Scholar
• Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466–470.
   PubMed Web of Science ®Google Scholar
• Perri F, Pezzullo L, Chiofalo MG, et al. Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol Hematol. 2015;94(1):55–63.
   PubMed Web of Science ®Google Scholar
• Zoghlami A, Roussel F, Sabourin JC, et al. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131:7–13.
   PubMed Web of Science ®Google Scholar
• Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. 2013;18(8):926–932.
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–262.
   PubMed Web of Science ®Google Scholar
• Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113:2440–2447.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Saenko V, Yamashita S, et al. Radiation-induced thyroid cancers: overview of molecular signatures. Cancers (Basel). 2019;11:1290.
   Web of Science ®Google Scholar
• Santoro M, Moccia M, Federico G, et al. RET gene fusions in malignancies of the thyroid and other tissues. Genes (Basel). 2020;11:424.
   Web of Science ®Google Scholar
• Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–2326.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang Y, Feng D, et al. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget. 2017;8(28):45784–45792.
   PubMedGoogle Scholar
• Ricarte-Filho JC, Li S, Garcia-Rendueles MER, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013;123(11):4935–4944.
   PubMed Web of Science ®Google Scholar
• Hao Z, Wang P. Lenvatinib in Management of Solid Tumors. Oncologist. 2020;25:e302–e310.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Newbold K, Licitra L, et al. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev. 2018;69:164–176.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 372(7): :621–630. 2015.
   Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
   PubMedGoogle Scholar
• Nakazawa Y, Kawano S, Matsui J, et al. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model. Cancer Science. 2015;106(2):201–207.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim S-M, Chang H-J, et al. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer. BMC Cancer. 2018;18(1):956.
   PubMedGoogle Scholar
• Suzuki K, Iwai H, Utsunomiya K, et al. Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor. Exp Cell Res. 2021;398(1):112390.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al., A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 121(16): 2749–2756. 2015.
   PubMed Web of Science ®Google Scholar
• Kiyota N, Schlumberger M, Muro K, et al. Subgroup analysis of Japanese patients in a Phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science. 2015;106(12):1714–1721.
   PubMed Web of Science ®Google Scholar
• Robinson B, Schlumberger M, Wirth LJ, et al. Characterization of tumor size changes over time from the Phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016;101(11):4103–4109.
   PubMed Web of Science ®Google Scholar
• Brose MS, Worden FP, Newbold KL, et al., Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 35(23): 2692–2699. 2017.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kiyota N, Yamazaki T, et al. A phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15(7):717–726.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Iwasaki H, Takasaki H, et al. Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer. Medicine (Baltimore). 2019;98(10):e14774.
   PubMed Web of Science ®Google Scholar
• Gianoukakis AG, Dutcus CE, Batty N, et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer. 2018;25(6):699–704.
   PubMed Web of Science ®Google Scholar
• Skovlund E, Leufkens HGM, Smyth JF. The use of real-world data in cancer drug development. Eur J Cancer. 2018;101:69–76.
   PubMed Web of Science ®Google Scholar
• De Leo S, Di Stefano M, Persani L, et al. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine. 2021;72(2):462–469.
   PubMed Web of Science ®Google Scholar
• Jerkovich F, Califano I, Bueno F, et al. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine. 2020;69(1):142–148.
   PubMed Web of Science ®Google Scholar
• Masaki C, Sugino K, Saito N, et al. Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid. 2020;30(2):214–221.
   PubMed Web of Science ®Google Scholar
• Rendl G, Sipos B, Becherer A, et al. Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria. Int J Endocrinol. 2020;2020:8834148.
   PubMed Web of Science ®Google Scholar
• Kish JK, Chatterjee D, Wan Y, et al. Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer: a real-world study of clinical effectiveness in the United States. Adv Ther. 2020;37(6):2841–2852.
   PubMed Web of Science ®Google Scholar
• Denaro N, Latina A, Cesario F, et al. Lenvatinib long-term responses in refractory thyroid cancer: our mono-institutional real-life experience with the multidisciplinary approach and review of literature. Oncology. 2019;97(4):206–210.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Tahara M, Robinson B, et al. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018;124(11):2365–2372.
   PubMed Web of Science ®Google Scholar
• Steeghs N, Gelderblom H, Roodt JOT, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470–3476.
   PubMed Web of Science ®Google Scholar
• Wei W, Jin H, Chen Z-W, et al. Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries. J Cardiovasc Pharmacol. 2004;44(5):615–621.
   PubMed Web of Science ®Google Scholar
• Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675–681.
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605–622.
   PubMed Web of Science ®Google Scholar
• Tahara M, Brose MS, Wirth LJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61–68.
   PubMed Web of Science ®Google Scholar
• Reed N, Glen H, Gerrard G, et al. Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer. Clin Oncol (R Coll Radiol). 2020;32:e145–e153.
   PubMed Web of Science ®Google Scholar
• Platini F, Cavalieri S, Alfieri S, et al. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Endocrine. 2021 Apr 2. https://doi.org/10.1007/s12020-021-02702-4.
   Google Scholar
• Resteghini C, Cavalieri S, Galbiati D, et al. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. 2017;31:349–361. Best Pr Res Clin Endocrinol Metab.
   PubMed Web of Science ®Google Scholar
• Paragliola RM, Corsello A, Del Gatto V, et al. Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application. Expert Opin Drug Discov. 2020;15:11–26.
   PubMed Web of Science ®Google Scholar
• Yun KJ, Kim W, Kim EH, et al. Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer. Endocrinol Metab (Seoul). 2014;29:388–393.
   PubMedGoogle Scholar
• Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25.
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Toda S, Suganuma N, et al. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Mol Clin Oncol. 2020;12:138–143.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Arnedos M, Andre F, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3:264–279.
   PubMed Web of Science ®Google Scholar
• Aghajani M, Graham S, McCafferty C, et al. Clinicopathologic and prognostic significance of programmed cell death ligand 1 expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis. Thyroid. 2018;28:349–361.
   PubMed Web of Science ®Google Scholar
• Ulisse S, Tuccilli C, Sorrenti S, et al. PD-1 Ligand Expression in Epithelial Thyroid Cancers: potential Clinical Implications. Int J Mol Sci. 2019;20:1405.
   Web of Science ®Google Scholar
• Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer. 2019;19:196.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.
   PubMed Web of Science ®Google Scholar
• Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31:1076–1085.
   PubMed Web of Science ®Google Scholar